Analysts Lift Twist Bioscience Price Target by Nearly 30%
The average one-year consensus price target for Twist Bioscience (NASDAQ GS: TWST; BIT: 1TWST) has been raised to $153.59 per share, marking a significant shift in Wall Street's near-term outlook for the synthetic biology company.
The revision represents a 29.51% increase over the prior aggregate estimate of $118.60, which had been set on September 29, 2026. The updated figure is drawn from a compilation of individual analyst price targets, reflecting a broadening of bullish sentiment among the sell-side professionals who cover the stock.
What Drives the Revision
The jump from $118.60 to $153.59 signals that multiple analysts have individually raised their own target prices within the same reporting window, pulling the aggregate average upward by almost a third. While the source data does not isolate a single catalyst, revisions of this magnitude in a one-month window typically follow developments such as updated earnings guidance, pipeline progress, or a reassessment of the company's long-term revenue trajectory in the gene-synthesis and synthetic-biology space.
For investors tracking the stock, the new consensus sits well above the prior level and suggests that the analyst community now expects a materially higher valuation for TWST over the coming twelve months. The breadth of the revision—spanning several independent desks—adds credibility to the move, as it is not attributable to a single outlier estimate.
Implications for Shareholders
A roughly 30% upward repricing of the consensus target can influence institutional positioning and retail sentiment in the near term. Investors who entered at or near the September 29 estimate may view the new $153.59 figure as confirmation that their thesis aligns with the broader Street view. Conversely, those who remain skeptical should note that consensus targets are backward-looking aggregates and do not constitute a guarantee of price performance.
Twist Bioscience, listed on both the Nasdaq Global Select market and the Berlin Stock Exchange, operates at the intersection of DNA synthesis, biomanufacturing, and genomic tools. Any movement in its analyst consensus therefore carries weight for the broader synthetic-biology sector, where valuation multiples are sensitive to pipeline milestones and commercialization timelines.
Traders and long-term investors should continue to monitor subsequent analyst notes, as further revisions—upward or downward—will refine the picture of where the Street expects TWST to trade over the next year.